Plaque Psoriasis Drug MOA Animation

Created for Arcutis Biotherapeutics

A shot from MOA animation of Arcutis’ proprietary drug delivery technology ZORYVE (roflumilast) cream. It shows a psoriatic skin cube with Zoryve (roflumilast) cream on its surface. © 2022 Arcutis Biotherapeutics, Inc.

Still image from an animation about the MOA of Zoryve. It shows the drug delivery vehicle delivering roflumilast to the lipid layer between corneocytes in the stratum corneum of the skin.

A shot from the commercial animation of Arcutis’ proprietary drug delivery technology ZORYVE (roflumilast) cream. This shot is a cross section view of roflumilast in a crystal emulsion butting up against the bilipid layers of the stratum corneum. Lipid bilayers of the emulsion and the ceramides in the skin are combining and roflumilast molecules are migrating from the emulsion into the skin. © 2022 Arcutis Biotherapeutics, Inc.

Still image from an animation about the MOA of Zoryve. It shows roflumilast binding to enzyme PDE4.

A shot from the commercial animation of Arcutis’ proprietary drug delivery technology ZORYVE (roflumilast) cream that covers roflumilast’s mechanism of action. This shot shows a roflumilast molecule binding to PDE4 within the immune cell environment. © 2022 Arcutis Biotherapeutics, Inc.

Still image from the Zoryve MOA animation. It shows roflumilast diffusing in the epidermis to immune cells.

A shot from the commercial animation of Arcutis’ proprietary drug delivery technology ZORYVE (roflumilast) cream. This shot is a view of immune cell and adjacent keratinocyte. © 2022 Arcutis Biotherapeutics, Inc.

Title screen from the Zoryve MOA animation

The final screen from the commercial animation of Arcutis’ proprietary drug delivery technology ZORYVE (roflumilast) cream. Final screen includes a 3d molecule of rolfumilast and summarizes advantages of Zoryve cream. © 2022 Arcutis Biotherapeutics, Inc.

The project

In this plaque psoriasis drug MOA animation created for dermatologists, we present the innovative drug delivery mechanism of Zoryve. In dermatology, the role of the proinflammatory enzyme phosphodiesterase 4 (PDE4) in plaque psoriasis psoriasis is well established. However, inhibiting PDE4 with topical drugs has so far been unsuccessful. This is due to the difficulty in crossing the epidermis without disrupting its barrier function. Arcutis solved this with a novel formulation of roflumilast that facilitates delivery to the cells driving inflammation in plaque psoriasis. To explain this innovative drug delivery process, we worked with Arcutis scientists and devised a visual model of the emulsions that house roflumilast. We then sectioned these emulsions and the lipid matrix between corneocytes. Next, we animated the roflumilast molecules diffusing passively between stratum corneum cells to reach their target. In a second plaque psoriasis drug MOA animation (not shown), our medical animators depict how roflumilast acts to inhibit PDE4 activity.

Created for
Arcutis Biotherapeutics

View Animation